From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching
Patients with HER2+ breast cancer (BC) can receive pertuzumab/trastuzumab (PT) subcutaneous (SC) or intravenous (IV) with similar efficacy. This study explores patients and healthcare professionals (HCPs) perceptions post-PT-SC implementation, alongside a pharmacoeconomic analysis.
This multicentre observational study included semi-structured interviews with HER2+ BC patients (SC or IV) and HCPs from six Lombardy (Italy) BC units plus a pharmacoeconomic analysis of organisational and cost impact. Data were analysed using descriptive statistics and thematic analysis to identify key themes: safety perception, treatment comfort, and trust issues.